[go: up one dir, main page]

MX2019003943A - Farmaco eficaz para un metodo linfogeno de administracion de farmaco. - Google Patents

Farmaco eficaz para un metodo linfogeno de administracion de farmaco.

Info

Publication number
MX2019003943A
MX2019003943A MX2019003943A MX2019003943A MX2019003943A MX 2019003943 A MX2019003943 A MX 2019003943A MX 2019003943 A MX2019003943 A MX 2019003943A MX 2019003943 A MX2019003943 A MX 2019003943A MX 2019003943 A MX2019003943 A MX 2019003943A
Authority
MX
Mexico
Prior art keywords
drug
lymphogenous
effective
administrating method
administered
Prior art date
Application number
MX2019003943A
Other languages
English (en)
Inventor
Kodama Tetsuya
Mori Shiro
Nohara Go
Original Assignee
Univ Tohoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tohoku filed Critical Univ Tohoku
Publication of MX2019003943A publication Critical patent/MX2019003943A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proporciona una composición farmacéutica conveniente para administración de fármacos anticáncer en nodos linfáticos por medio de sistemas de suministro de fármaco linfático; una composición farmacéutica para el tratamiento terapéutico o profiláctico de cáncer a ser administrada en nodos linfáticos, comprende al menos un fármaco anticáncer seleccionado del grupo que consiste en antimetabolitos y alcaloides vegetales anticáncer como un principio activo.
MX2019003943A 2016-10-05 2017-08-31 Farmaco eficaz para un metodo linfogeno de administracion de farmaco. MX2019003943A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016197614 2016-10-05
PCT/JP2017/031483 WO2018066278A1 (ja) 2016-10-05 2017-08-31 リンパ行性薬剤投与法で有効な薬剤

Publications (1)

Publication Number Publication Date
MX2019003943A true MX2019003943A (es) 2019-09-18

Family

ID=61831759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003943A MX2019003943A (es) 2016-10-05 2017-08-31 Farmaco eficaz para un metodo linfogeno de administracion de farmaco.

Country Status (12)

Country Link
US (2) US11559526B2 (es)
EP (1) EP3524269B1 (es)
JP (1) JP6960637B2 (es)
KR (1) KR102431011B1 (es)
CN (1) CN110022899A (es)
AU (1) AU2017340350B9 (es)
BR (1) BR112019006949A2 (es)
CA (1) CA3039442C (es)
MX (1) MX2019003943A (es)
RU (1) RU2759640C2 (es)
TW (1) TWI754666B (es)
WO (1) WO2018066278A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60190769A (ja) * 1984-03-09 1985-09-28 Sagami Chem Res Center ５−フルオロウラシルの製造方法
DE60043355D1 (de) * 1999-10-22 2009-12-31 Procter & Gamble Verbundvliesstoff der einen vliesstoff aus fasern aus ethylen-propylen-copolymer mit zufälliger verteilung benutzt
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
JP2005533748A (ja) 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ，インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法
KR20080003322A (ko) * 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 도세탁셀 및 이의 유사체의 나노입자 배합물
CN101045163B (zh) 2006-03-29 2011-03-30 重庆莱美药业股份有限公司 一种高分子抗癌前药及其制备方法和用途
JP5429642B2 (ja) * 2007-06-12 2014-02-26 アレン，クリスティン 薬剤の局所導出を対象とした注射可能なポリマー／脂質ブレンド
EP2025333A1 (en) * 2007-08-14 2009-02-18 Pharmatex Italia Srl Injectable pharmaceutical formulation of taxoids
CA2722376C (en) * 2008-04-22 2017-05-30 Fidia Farmaceutici S.P.A. Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
ES2687705T3 (es) * 2012-07-19 2018-10-26 Fujifilm Corporation Composición líquida que contiene un principio activo a base de taxano, proceso de producción de la misma y preparación medicinal líquida
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
EP3677283A4 (en) * 2017-08-31 2021-05-12 Tohoku University Appropriate osmotic pressure range of solution containing drug effective in lymphatic drug delivery system

Also Published As

Publication number Publication date
US11559526B2 (en) 2023-01-24
EP3524269A4 (en) 2020-06-17
US20230119275A1 (en) 2023-04-20
JPWO2018066278A1 (ja) 2019-07-18
TW201813668A (zh) 2018-04-16
AU2017340350B2 (en) 2022-12-22
BR112019006949A2 (pt) 2019-07-02
RU2759640C2 (ru) 2021-11-16
KR20190064570A (ko) 2019-06-10
CA3039442A1 (en) 2018-04-12
JP6960637B2 (ja) 2021-11-05
US20200038400A1 (en) 2020-02-06
EP3524269B1 (en) 2024-02-21
CN110022899A (zh) 2019-07-16
RU2019109965A3 (es) 2020-12-14
EP3524269A1 (en) 2019-08-14
KR102431011B1 (ko) 2022-08-09
RU2019109965A (ru) 2020-11-06
AU2017340350B9 (en) 2023-02-09
WO2018066278A1 (ja) 2018-04-12
TWI754666B (zh) 2022-02-11
AU2017340350A1 (en) 2019-05-02
CA3039442C (en) 2023-07-04

Similar Documents

Publication Publication Date Title
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
EP4512394A3 (en) Dosage forms and use thereof
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EP3168214A4 (en) Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
AU2017276588A1 (en) Physiologically balanced injectable formulations of fosnetupitant
MX390755B (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
ZA202003904B (en) Drug delivery system
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
MX2019003943A (es) Farmaco eficaz para un metodo linfogeno de administracion de farmaco.
FI20155779A7 (fi) Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
WO2019098691A3 (ko) 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법
IN2013MU03370A (es)
PH12016502540A1 (en) Pharmaceutical dosage forms
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.
MX387252B (es) EL USO DE DERIVADOS DE QUINOLINONAS QUE TIENE UNA ACTIVIDAD DE INHIBICIÓN DE LA FORMACIÓN DEL COMPLEJO DE C-Myc/Max/ADN EN EL TRATAMIENTO DE CANCER.
RU2017140779A (ru) Композиции для лечения рака
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
UA104615U (uk) Спосіб лікування токсокарозу
MY203919A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion